Quick Answer
Acurx Pharmaceuticals, Inc. reported Research And Development Expense of $1.83 million for the year ending 2025.
- Acurx Pharmaceuticals, Inc. showed a decrease of -66.1% in Research And Development Expense from 2024 to 2025.
- This data is from Acurx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $400.7 thousand | Q3 2020: $660.0 thousand | Q1 2021: $91.9 thousand | Q2 2021: $95.1 thousand | Q3 2021: $1.13 million | Q1 2022: $818.9 thousand | Q2 2022: $911.7 thousand | Q3 2022: $1.59 million | Q1 2023: $1.02 million | Q2 2023: $1.74 million | Q3 2023: $1.35 million | Q1 2024: $1.56 million | Q2 2024: $1.83 million | Q3 2024: $1.20 million | Q1 2025: $598.8 thousand | Q2 2025: $524.2 thousand | Q3 2025: $429.7 thousand.
- Over the full 6 years of available data (2020 to 2025), Acurx Pharmaceuticals, Inc.'s Research And Development Expense has declined by 16.7%.
- Historical annual values: Fiscal year 2025: $1.83 million | Fiscal year 2024: $5.40 million | Fiscal year 2023: $6.04 million | Fiscal year 2022: $4.75 million | Fiscal year 2021: $2.03 million | Fiscal year 2020: $2.20 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: